Funded Biotechnology Startups in Mountain View
Disclosed funding amounts in Mountain View Biotechnology are topped by DNAnexus’s $200M round dated 2022-03-08; that figure dwarfs the next-largest disclos…
Disclosed funding amounts in Mountain View Biotechnology are topped by DNAnexus’s $200M round dated 2022-03-08; that figure dwarfs the next-largest disclosed amounts (IGM Biosciences at $107M on 2023-06-22 and Amunix at $117M on 2021-03-04 are both below $200M). At the low end, Magic Lifescience’s $160K round on 2024-09-03 is the smallest disclosed amount shown, creating a wide spread between the largest and smallest disclosed rounds.
The dated entries also form two noticeable clusters: several rounds sit in 2022 (DNAnexus on 2022-03-08, turn.bio on 2022-04-11, Ceribell on 2022-09-21), while more recent activity appears in 2025–2026 (Swaza on 2026-03-30, Curve Biosciences on 2025-10-30, and Aerin Medical on 2025-01-13). All 10 rows list Biotechnology in Mountain View, and stage labels are uneven: 5 of the 10 rows use “Series Unknown” and 1 additional row is explicitly “undisclosed,” alongside labeled Seed, Series A/B/C, Series H, and a “Venture” label. The set spans from 2021-03-04 (Amunix) to 2026-03-30 (Swaza).
Most recent rounds
10 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Mountain View biotech list, and how does it compare to the rest of the disclosed amounts?
DNAnexus’s $200M on 2022-03-08 is the largest disclosed amount shown and is well above the other disclosed highs, including IGM Biosciences at $107M (2023-06-22) and Amunix at $117M (2021-03-04). The smallest disclosed amount is Magic Lifescience’s $160K on 2024-09-03.
Are rounds clustered in a specific time window rather than evenly spread across years?
Yes. Three of the 10 rows fall in 2022 (DNAnexus 2022-03-08 at $200M; turn.bio 2022-04-11 as undisclosed; Ceribell 2022-09-21 at $50M). A second concentration appears in the newest years, with 2025–2026 entries including Aerin Medical on 2025-01-13 ($33M), Curve Biosciences on 2025-10-30 ($40M), and Swaza on 2026-03-30 ($400K).
How often are stage labels missing or not standardized (Series Unknown or undisclosed), relative to labeled rounds?
Stage is not consistently specified: 5 of the 10 rows are labeled “Series Unknown” (Aerin Medical 2025-01-13, Magic Lifescience 2024-09-03, IGM Biosciences 2023-06-22, turn.bio 2022-04-11 has “Venture - Series Unknown,” and IGM Biosciences is one of the Unknown entries), and 1 row is explicitly “undisclosed” (turn.bio 2022-04-11). The remaining 4 rows have specific labels such as Seed, Series A/B/C, and Series H.
Which stage label group has the clearest disclosed amounts, and does any single stage look dominant among the labeled entries?
Among the labeled stages, Seed appears twice with widely separated outcomes: Magic Lifescience is “Series Unknown” (not Seed), but Seed entries are Swaza (Seed, $400K on 2026-03-30) and Rejuvenation Technologies (Seed, $11M on 2023-09-06). Other labeled rounds include major disclosed financings like Ceribell’s Series C at $50M (2022-09-21) and DNAnexus’s Series H at $200M (2022-03-08), but there is no single stage that clearly dominates the disclosed amount range.
Are there notable funding outliers that could affect comparisons or deal-screening assumptions?
Yes: DNAnexus at $200M (2022-03-08) is an outlier on the high end, while Magic Lifescience at $160K (2024-09-03) is the smallest disclosed amount. Additionally, turn.bio on 2022-04-11 is an outlier for data completeness with “undisclosed,” limiting comparability even though it is listed in the same Mountain View biotech context.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.